A Systematic Review and Meta-Analysis of an Emerging Therapy against COVID-19: Is Convalescent Plasma a Hidden Gem Not Yet Optimized?

Sarfraz, Azza; Sarfraz, Zouina; Razzack, Aminah Abdul; Hathaway, Donald; Thevuthasan, Sindhu; Makkar, Sarabjot Singh; Paul, Trissa; Patel, Gaurav; Sana, Muhammad Khawar; Sarfraz, Muzna; Richter, F.; Gonzalez, Marcos A. Sanchez

doi:10.9734/jpri/2020/v32i4731113

Cited by 2 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Serious COVID-19, including severe and critical types, is usually characterized by severe respiratory disease, multiple organ dysfunction, immune cell exhaustion, and local or systemic hyperinflammation. [31][32][33] In this period, the pathophysiologic damage to the body derives more from the host's own immune system rather than from the virus itself. Consequently, immunomodulatory treatment becomes pertinent.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of thymosin-α-1 in patients with COVID-19: A systematic review and meta-analysis

Wang,

Chen

2023

Eur J Inflamm

View full text Add to dashboard Cite

Objective To identify whether thymosin-α-1 (Tα1) is effective in patients with Coronavirus disease 2019 (COVID-19) and to determine a suitable population for Tα1 treatment. Methods We included studies with ≥10 cases and adults (aged ≥18 years) with laboratory-confirmed SARS-CoV-2 infection, data on mortality or length of hospitalization, disease severity, and study location, while excluded pregnant and breastfeeding women and minors. Publications were searched from November 1, 2019, to July 5, 2023, in six databases, including PubMed, Web of Science, Embase, Cochrane Library, China Knowledge Resource Integrated Database, and Wanfang Database. We separately utilized Newcastle-Ottawa Scale and Cochrane handbook methodology to evaluate risk of bias and used Review Manager (version 5.4, Cochrane Collaboration, Copenhagen, Denmark) to present and synthesize results. Relative risks (RR) and Standardized Mean Difference (SMD) with 95% confidence intervals (CI) were analyzed for dichotomous variables and continuous variables, respectively. Results Nine studies (participants = 5417) were included. No significant differences were found in mortality (nine studies; n = 5417; RR = 0.95; 95% CI: 0.56, −1.60; p = .84; I2 = 90%) or length of hospitalization (four studies; n = 3688; SMD = 0.16; 95% CI: −0.38, −0.69; p = .57; I2 = 96%) between patients with COVID-19 who did and did not receive Tα1. Participants were divided by the severity of the disease (serious and non-serious) and study location. Among the serious group, the incidence of death among patients who received Tα1 treatment was 0.67 times that of patients who did not receive Tα1 treatment (four studies; n = 1230; RR: 0.67; 95% CI: 0.58, −0.77; p < .00,001; I2 = 0%). There was no significant difference in length of hospitalization between the groups (two studies; n = 410; SMD = 0.66; 95% CI: −0.06, −1.38; p = .07; I2 = 87%). Among the non-serious group, compared to not having Tα1 treatment, receiving Tα1 treatment reduced hospitalization length (two studies; n = 3670; SMD = −0.28; 95% CI: −0.41, −0.14; p < .0001; I2 = 51%), while no significant difference in mortality (three studies; n = 3775; RR = 1.06; 95% CI: 0.22, −5.03; p = .94; I2 = 89%). Moreover, there was no significant difference between subgroups when divided by study locations (Studies within China: seven studies; n = 5263; RR = 1.14; 95% CI: 0.64, −2.04; p = .65; I2=92%; Studies outside of China: two studies; n = 154; RR = 0.41; 95% CI: 0.14, −1.24; p = .11; I2 = 51%). Discussion For patients with serious types of COVID-19, Tα1 significantly decreased mortality, which supports the utilization of Tα1 in patients with severe and critical types of COVID-19. Moreover, regarding hospitalization length, patients with non-serious COVID-19 who used Tα1 reduced their hospitalization length compared to those that did not use Tα1. However, these results have high heterogeneity and limited generalizability.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy of thymosin-α-1 in patients with COVID-19: A systematic review and meta-analysis

Wang,

Chen

2023

Eur J Inflamm

View full text Add to dashboard Cite

show abstract

“…Studies have found improved clinical outcomes and higher extubation rates in hospitalized Covid-19 patients with ARDS in the ICU. In addition, they provided anti-coagulant properties in patients presented with DIC, thrombotic microangiopathy, and MODS [38]. Hypotension is the most common adverse effect of TPE.…”

Section: Cpfa In Critically Ill Covid-19mentioning

confidence: 99%

Untitled

Army¹,

Violetta²

2022

J. Med. Chem. Sci.

View full text Add to dashboard Cite

The Corona-19 virus disease continues to cause an increasing number of deaths, mainly due to acute respiratory disorders. The high pandemic mortality and morbidity prompted clinicians to seek suitable adjunctive therapeutic methods to eliminate high cytokine levels effectively. This study aimed to review the combined plasma filtration adsorption (CPFA) technology and its potential efficacy in treating critically ill Covid-19. CPFA combines plasma separation, adsorption, and hemofiltration techniques that meet the need to remove substances such as cytokines. Findings from the report suggest an immune dysregulation known as cytokine storm syndrome plays a role in severe and critically ill Covid-19 patients. Extracorporeal blood purification targets cytokine elimination and is preferred as a bridging strategy to improve survival. Combined adsorption plasma filtration (CPFA) can remove various substances, including cytokines, without depleting physiologically essential proteins. CPFA can be considered and assessed in clinical trials to treat critically ill Covid-19 patients. Paired Plasma Filtration Adsorption (PPFA) can be viewed as a potentially effective therapy in treating Covid-19 patients in critical condition.

show abstract

A Systematic Review and Meta-Analysis of an Emerging Therapy against COVID-19: Is Convalescent Plasma a Hidden Gem Not Yet Optimized?

Cited by 2 publications

References 15 publications

Efficacy of thymosin-α-1 in patients with COVID-19: A systematic review and meta-analysis

Efficacy of thymosin-α-1 in patients with COVID-19: A systematic review and meta-analysis

Untitled

Contact Info

Product

Resources

About